ClinicalTrials.gg
RecruitingNCT06730386Updated Mar 6, 2025

A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors

A Phase 1 interventional study of AK138D1 in Solid Cancer, sponsored by Akeso. Recruiting at 4 sites in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by Akeso · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open-label, first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK138D1 in subjects being treated for advanced solid tumors.

Read the detailed description

This study is comprised of two parts: the dose-escalation and dose-expansion stages. Dose-escalation stage aims to determine the MTD/MAD, while the dose-expansion stage is designed to establish the RP2D.

02

Conditions studied

  • Solid Cancer
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject must sign the written form (ICF) voluntarily;
  2. At enrollment, aged ≥ 18 to ≤ 75 years, both males and females are eligible;
  3. performance status score of 0 or 1;
  4. Has a of ≥ 3 months;
  5. Subjects who have or cytologically diagnosed locally advanced or solid tumor, which Is to or intolerant to standard treatment;
  6. At least 1 as per v1.1 that is suitable for repeated accurate measurement.
  7. Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Prior human epidermal growth factor receptor 3 (HER3) -targeted therapies, including antibodies, antibody-drug conjugates (ADCs), chimeric antigen receptor T-cell immunotherapy (CAR-T), and others;
  2. Concomitant participation in another clinical study, unless it is a non-interventional clinical study or the follow-up period of an interventional study;
  3. Presence of active central nervous system (CNS) .
  4. Patients with a history of non-infectious pneumonitis requiring systemic therapy; a history of interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis); currently suffering from ILD/pneumonitis or suspected of having such diseases based on imaging during screening;
  5. or attenuated live vaccines administered within 4 weeks prior to the first dose, or planned to be administered during the study; use of inactivated vaccines is allowed;
  6. Untreated subjects with active (HBsAg positive and HBV-DNA exceeding 1000 copies/mL (200 IU/mL) and above the lower limit of detection). For HBsAg-positive subjects, anti-hepatitis B therapy is required during the study; subjects with active (HCV antibody positive and HCV-RNA levels above the lower limit of detection) is also an exclusion;
  7. Known active pulmonary tuberculosis (TB); subjects with suspected active TB must undergo appropriate clinical assessment to rule out the presence of active disease;
  8. Active syphilis infection;
  9. Subjects with known allergy to any component of any study drug; and with a history of known severe reactions to other monoclonal antibodies;
  10. Other reasons for ineligibility as evaluated by the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    AK138D1

    AK138D1 will be administered in pre-specified dose levels.

    Drug: AK138D1

Interventions

  • DrugAK138D1

    Enrolled subjects will receive intravenous infusion (IV) of AK138D1 according to the dosing regimen specified in their cohort.

06

What researchers measure

Primary outcomes

  1. AEs

    Incidence and severity of participants with adverse events

    Time frame: Up to approximately 2 years

  2. Dose-limiting toxicity (DLT)

    Occurrence of DLTs and determination fo maximum tolerated dose (MTD)

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Cmax and Cmin of AK138D1

    AK138D1 serum drug concentrations in subjects at different time points after administration.

    Time frame: Up to approximately 2 years

  2. Anti-drug antibodies (ADA)

    Number of subjects with detectable anti-drug antibodies (ADA).

    Time frame: Up to approximately 2 years

  3. Objective Response Rate (ORR) assessed by investigator per RECIST v1.1

    ORR is the proportion of subjects with complete response(CR) or partial response(PR) , assessed by investigators based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  4. Disease Control Rate (DCR) assessed by investigator per RECIST v1.1

    Disease control rate (DCR) assessed according to RECIST v1.1.

    Time frame: Up to approximately 2 years

  5. Duration of response (DoR) assessed by the investigator per RECIST v1.1

    Duration of response (DoR) assessed according to RECIST v1.1.

    Time frame: Up to approximately 2 years

  6. Time to response (TTR) assessed by the investigator per RECIST v1.1

    Time to response (TTR) is defined as the time to response based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  7. Progression Free Survival (PFS) assessed by investigator per RECIST v1.1

    PFS is defined as the time from randomization to the first documented disease progression (per RECIST v1.1 criteria) assessed by investigators or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  8. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 2 years

07

Study locations

2 of 4 sites recruiting
  • Blacktown Hospital-Blacktwon Cancer and Haematology Centre
    Blacktown, New South Wales 2148, Australia
    Not yet recruiting
  • Macquarie University
    North Ryde, New South Wales 2109, Australia
    Not yet recruiting
  • ICON Cancer Centre South Brisbane
    South Brisbane, Queensland 4101, Australia
    Recruiting
    • Jermaine Coward, MD · ContactJim.Coward@icon.team · 0737374500
    • Jermaine Coward, MD · Principal investigator
  • Peninsula & South Eastern Haematology and Oncology Group
    Frankston, Victoria 3199, Australia
    Recruiting
    • Vinod Ganju, MD · Contactvg@paso.com.au · 0397815244
    • Vinod Ganju, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Feb 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 12, 2024
StartActual
Feb 24, 2025
Primary completionEst.
Feb 26, 2028
CompletionEst.
Aug 30, 2028
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06730386
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Dec 12, 2024
Start date
Feb 24, 2025
Primary completion
Feb 26, 2028 (estimated)
Completion
Aug 30, 2028 (estimated)
Last update
Mar 6, 2025

Study contacts

Wenting Li, MD
Contact
wenting01.li@akesobio.com
+86-18116403289

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion